Australia markets open in 17 minutes

SAVA Jan 2025 22.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
8.500.00 (0.00%)
As of 09:55AM EST. Market open.
Full screen
Previous close8.50
Expiry date2025-01-17
Day's range8.50 - 8.50
Contract rangeN/A
Open interest165

    Cassava Sciences Inc (SAVA) Reports Full-Year 2023 Financial Results

    Key Financials and Corporate Updates Highlighted

  • GlobeNewswire

    Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

    $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:

  • GlobeNewswire

    No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

    ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study